J Neuroinflammation. 2016 Nov 1;13(1):281. Jarius S1, Kleiter I2, Ruprecht K3, Asgari N4, Pitarokoili K2, Borisow N5,6, Hümmert MW7, Trebst C7, Pache F5,6, Winkelmann A8,…
J Neuroinflammation. 2016 Sep 26;13(1):279. Abstract BACKGROUND: Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been suggested to play a role in a subset of patients…
Anti-aquaporin-4 antibody in Chinese patients with central nervous system inflammatory demyelinating disorders. Long Y, Qiu W, Hu X, Peng F, Lu Z, Wang Y, Yang Y. Source Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou 510630, Guangdong Province, People’s Republic of China; Department of Neurology, Clinical College, The First Affiliated Hospital of Guangdong Pharmaceutical University, 19 Nonglinxia Road, Guangzhou 510080, Guangdong Province, People’s Republic of China.
Variable results after rituximab in neuromyelitis optica. Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS. Abstract Our objective was to assess the efficacy of rituximab (RTX) in neuromyelitis optica (NMO)
Multiple sclerosis: clinical aspects Sunday, May 29, 2011, 12:00 – 13:00 Neuromyelitis optica spectrum disorder: the importance of NMO-IgG in clinical practice M. Radaelli, V
Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using optical coherence tomography Mario L.R. Monteiro 1, Danilo B
Analysis of 103 Hungarian patients with neuromyelitis optica spectrum disease M. Banati, E. Koszegi, P
OBJECTIVE: To evaluate the retinal nerve fiber layer (RNFL) thickness and macular volume in neuromyelitis optica (NMO) spectrum patients using optical coherence tomography (OCT). BACKGROUND: OCT can quantify damage to retinal ganglion cell axons and can identify abnormalities in multiple sclerosis and optic neuritis (ON) eyes.
Introduction: idiopathic acute transverse myelitis (ATM) is clinically characterized by partial or complete spinal cord syndromes, variable remission rate and a monophasic or recurrent clinical course. Partial forms are traditionally associated with Multiple Sclerosis (MS) while complete myelitis to neuromyelitis optica (NMO). The discovery of an antibody called anti-AQP4 was an important tool to differentiate these two conditions.
Background: Recurrent myelitis (rM) represents a pathogenetically heterogeneous group of inflammatory diseases with a selective involvement of the spinal cord. The recent description of NMO Ig-G antibody, the specific biomarker for Neuromyelites Optica (NMO), also in patients with recurrent myelitis with longitudinally extensive transverse spinal cord lesions (LETM), has brought to consider this disease an incomplete form of NMO (NMO Spectrum of Disorders). Methods: we retrospectively selected patients (pts) with rM attended our neurological department between January 2000 and March 2010
Objective: To estimate the frequency and prognostic value of NMO-IgG seropositivity in patients presenting with isolated optic neuritis (ON) and no prior neurological events. Background: The aquaporin-4-specific autoantibody, NMO-IgG, is a biomarker for neuromyelitis optica (NMO). We have shown that 38% of patients with longitudinally extensive transverse myelitis (LETM) and 20% of recurrent ON are seropositive and are at high risk for recurrence of ON and myelits
Backgrounds: The distinction between neuromyelitis optica (NMO) and multiple sclerosis (MS) has long been a debate in Asia. The most specific finding for NMO is a longitudinally extensive, central cord lesion on MRI in the setting of myelitis (LETM), which is very rare in MS. The MRI criterion for LETM (contiguous spinal cord lesion 3 or more segments in length) is crucial.